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Objectives: Informing cancer service delivery with
timely and accurate data is essential to cancer control
activities and health system monitoring. This study
aimed to assess the validity of ascertaining incident
cases and resection use for pancreatic and
periampullary cancers from linked administrative
hospital data, compared with data from a cancer
registry (the ‘gold standard’).
Design, setting and participants: Analysis of
linked statutory population-based cancer registry data
and administrative hospital data for adults (aged
≥18 years) with a pancreatic or periampullary cancer
case diagnosed during 2005–2009 or a hospital
admission for these cancers between 2005 and 2013
in New South Wales, Australia.
Methods: The sensitivity and positive predictive value
(PPV) of pancreatic and periampullary cancer case
ascertainment from hospital admission data were
calculated for the 2005–2009 period through
comparison with registry data. We examined the effect
of the look-back period to distinguish incident cancer
cases from prevalent cancer cases from hospital
admission data using 2009 and 2013 as index years.
Results: Sensitivity of case ascertainment from the
hospital data was 87.5% (4322/4939), with higher
sensitivity when the cancer was resected (97.9%,
715/730) and for pancreatic cancers (88.6%, 3733/
4211). Sensitivity was lower in regional (83.3%) and
remote (85.7%) areas, particularly in areas with
interstate outflow of patients for treatment, and for
cases notified to the registry by death certificate only
(9.6%). The PPV for the identification of incident cases
was 82.0% (4322/5272). A 2-year look-back period
distinguished the majority (98%) of incident cases
from prevalent cases in linked hospital data.
Conclusions: Pancreatic and periampullary cancer
cases and resection use can be ascertained from linked
hospital admission data with sufficient validity for
informing aspects of health service delivery and
system-level monitoring. Limited tumour clinical
information and variation in case ascertainment across
population subgroups are limitations of hospital-
derived cancer incidence data when compared with
population cancer registries.
INTRODUCTION
System-level monitoring of appropriateness
and quality of cancer care is an essential part
of cancer control.1 Population-based cancer
registries have a key role to play in system
performance reporting since they generally
Strengths and limitations of this study
▪ This study uses statutory population-based
cancer registry data as a ‘gold standard’ to
assess the ascertainment of cancer cases from
administrative hospital data.
▪ Sensitivity was examined by patient demographic
and tumour characteristics to identify potential
biases in case ascertainment from hospital data.
▪ A limitation is that we could only identify false
positives in the hospital data with a (non-
pancreatic) cancer case recorded on the cancer
registry, which may lead to an underestimate of
the number of false positives since false posi-
tives without any invasive cancer case recorded
on the registry were not identified.
▪ Look-back periods of up to 5 years were exam-
ined to distinguish incident cases from prevalent
cases in the hospital data.
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have a high level of completeness and accuracy of
cancer case information that is obtained from multiple
sources, including hospital admission and outpatient
data, pathology reports and death certificates.2
Increasingly, population-based cancer registries are
expanding their collection of clinical and treatment
information, or are linking to other clinical or treatment
databases, to gain more comprehensive data to produce
performance indicators for informing health service
delivery.3 A critical limitation is that the processes of
receiving notifications and compiling data in a
population-based cancer registry can be time-
consuming, with lag times typically of 18 months or
more before complete incidence data are available.4
This can reduce the utility of cancer registry data for
timely feedback on health system performance.
Population-level hospital admission data can be a
more timely data source for obtaining incident cancer
case data and evaluating treatment outcomes. However,
hospital data are usually collected for general adminis-
trative purposes and may lack the accuracy and com-
pleteness required for measuring patterns of cancer care
and outcomes. Validation of the data as being ‘fit for
purpose’ is therefore necessary.5 6 Another challenge is
that the diagnosis, treatment and management of
cancer can require multiple hospital admissions. As a
result, there is a need to distinguish incident cases from
prevalent cases. One approach is to only extract hospital
admissions with both a cancer diagnosis code and pro-
cedure or treatment code for the initial diagnosis or
treatment of the cancer.7 This approach may be needed
where an individual cannot be identified across multiple
hospital admission records. When multiple hospital
admission records for an individual can be identified,
the first admission with the cancer diagnosis code
recorded can be used to indicate an incident case.
The ascertainment of incident cancers from hospital
admission data has good validity for some cancers, such
as breast cancer, with sensitivity ranging from 77% to
86% and positive predictive values (PPVs) from 86% to
93%.8–10 Lower validity has been found for other
cancers, such as prostate and colorectal cancer, where
treatment is more likely to be in an ambulatory setting
or readmissions for prevalent cancers have not been dis-
tinguished from newly diagnosed cancer cases.8 11 12
The accuracy of case ascertainment from hospital data
depends on the quality of coding and completeness of
the hospital data, as well as on the patterns of hospital-
isation for the particular cancer.
Pancreatic cancer has poor survival and is among the
fifth most common cause of cancer death in Australia,
the USA and Europe.13–15 Pancreatic cancer surgery has
been the subject of system performance improvement
programmes in multiple jurisdictions with the aim of
improving outcomes for this cancer.16–19 Timely data
were required for the development of a service delivery
programme for pancreatic surgery for cancer in New
South Wales (NSW), Australia. Hospital admission data
have the potential to inform aspects of this programme,
but there are few studies examining the accuracy of
identifying pancreatic cancer cases from hospital admis-
sion data. One NSW study found good accuracy for the
recording of pancreatic cancer diagnoses in hospital
admission data,20 but the study was performed in only
one administrative health district and it is not known
whether these results are generalisable. The aim of the
present study was to determine the validity of administra-
tive hospital admission data for the ascertainment of
incident cases and resection use for pancreatic and peri-
ampullary cancers by measuring the sensitivity and PPV
using NSW cancer registry data as the ‘gold standard’
and to determine the look-back period required to dis-
tinguish incident cancer cases from prevalent cancer
cases in linked hospital data.
METHODS
Study population, design and data sources
The study population comprised NSW residents (aged
≥18 years) diagnosed with pancreatic or periampullary
cancer (International Statistical Classification of Diseases
and Related Health Problems, 10th Revision, Australian
Modification (ICD-10-AM) C17.0, C24-25). Periampullary
cancers were included because they have similar clinical
presentations and surgery to pancreatic cancer.21 NSW
has 7.5 million residents with the majority (4.8 million)
living in the greater Sydney metropolitan area. We used
linked de-identified data from the NSW Central Cancer
Registry (CCR), the Admitted Patient Data Collection
(APDC) and the NSW Admitted Patient, Emergency
Department Attendance and Deaths Register
(APEDDR).
The CCR is a statutory population-based cancer registry
of all incident primary invasive cancer cases (excluding
non-melanoma skin cancer) and in situ breast and mel-
anoma neoplasms diagnosed in NSW residents (referred
to here as ‘registry data’).22 Pathology laboratories, radio-
therapy and medical oncology departments, hospitals,
residential aged-care facilities and day procedure centres
are required to notify the registry with clinical informa-
tion about new cases of cancer and demographic details
about the person. The CCR is extending data collection
to include additional clinical and treatment information
and is increasing automation to improve efficiency and,
ultimately, timeliness. During this transformation process,
however, routine data processes were delayed which
affected availability of cancer incidence data, with 2009
the latest year available at the time of extraction.
The APDC (referred to here as ‘hospital data’) is a
compilation of patient demographic, admission and dis-
charge information, and diagnosis and procedure codes
for admissions to all NSW public and private hospitals.
Diseases, injuries, procedures and treatments in admit-
ted episodes of care are coded using ICD-10-AM and the
Australian Classification of Health Interventions
(ACHI). The coding of diagnoses and procedures is
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carried out according to the Australian Coding
Standards for ICD-10-AM and ACHI. This national
coding framework has been in place since the late
1990s.23
The APEDDR is a statutory public health and disease
register maintained by the NSW Ministry of Health. It
contains linked hospital (APDC) data and is the poten-
tial data source for timelier cancer incidence data in
NSW, with data available up to December 2013 at the
time of extraction.
Two separate probabilistic linkages (the registry to hos-
pital data; and the hospital data in the APEDDR) were
performed by the Centre for Health Record Linkage
(http://www.CHeReL.org.au) with an estimated false-
positive rate of 3 per 1000 and using a best practice
privacy-preserving protocol that separates personal iden-
tifiers from the analysis data sets.24 De-identified data
sets were provided to the researchers by the data
custodians.
Hospital coding of pancreatic and periampullary
cancer—comparison to cancer registry data
We extracted admissions with a pancreatic or periampul-
lary cancer diagnosis recorded in a primary or second-
ary diagnosis field between 2005 and 2009 in the linked
hospital admission data of all people with a cancer case
on the cancer registry between 1994 and 2009
(figure 1). We obtained from the registry month and
year of cancer diagnosis, sex, age at diagnosis, remote-
ness of residence,25 tumour histology type, primary site,
extent of disease (the furthest extent from notifications
within 4 months of diagnosis26) and best basis of diagno-
sis (the highest level of verification from notifications
within 4 months of diagnosis) for pancreatic and peri-
ampullary cancer cases diagnosed between 2005 and
2009. People who underwent pancreatectomy (ACHI
block 978) were identified from the linked hospital data.
Resections in the one calendar month prior to diagnosis
(to allow for minor inaccuracies in the month of diagno-
sis) or any time after diagnosis were included.
For the hospital data, we allocated a primary cancer
site using diagnosis codes recorded in admissions for
pancreatic and periampullary cancer. Inconsistencies in
the recording of primary site codes across different
admissions for the same person required the develop-
ment of an algorithm to allocate site. For pancreas
primary sites (C25), the most specific site in the pan-
creas was recorded. For example, if the site was ‘C25.9
pancreas, not otherwise specified’ in one admission and
‘C25.0 head of pancreas’ in another, then the latter
more specific site was allocated. When a periampullary
cancer (C17.0, C24) was recorded in one admission and
a pancreatic primary site in another, the primary site was
allocated as periampullary.
Ascertaining incident cases from linked hospital data
All admissions from 1 July 2000 (the earliest available
data) to 31 December 2013 with a pancreatic or periam-
pullary cancer diagnosis recorded in a primary or sec-
ondary diagnosis field were extracted from the linked
hospital data in the APEDDR. Non-NSW residents and
people aged <18 years at their first cancer admission
were excluded.
Analysis
Linked cancer registry and hospital data
Sensitivity of case ascertainment from the hospital data
was calculated as the proportion of cases on the registry
with an admission with a pancreatic or periampullary
cancer diagnosis recorded in the hospital data (true
positives) for the 2005–2009 period. Sensitivity was calcu-
lated by patient demographics (age at diagnosis
(grouped by 10-year age groups) and remoteness of resi-
dence (grouped as major city, inner regional, outer
regional, remote and very remote)) and tumour
characteristics (primary site, histology type, extent of
disease, best basis of diagnosis, resection status) to assess
if sensitivity varied by these characteristics. A PPV was
estimated as the proportion of people with a pancreatic
or periampullary cancer diagnosis recorded in the hos-
pital data who had an incident case recorded on the
registry for the 2005–2009 period.
We examined the diagnoses recorded for false-
negative and false-positive cases in the hospital and
Figure 1 Flow chart of case
ascertainment from the linked
registry and hospital data.
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registry data, respectively, to evaluate misclassification of
cancer cases. For false negatives, we examined diagnoses
in hospital admissions from the month prior to the
registry diagnosis date or any time after in the 2005–
2009 period. For false positives, we ascertained cases on
the registry diagnosed between 2005 and 2009, except
for pancreatic and periampullary cancers for which we
ascertained cases on the registry diagnosed between
1994 and 2004. Exact binomial CIs were calculated for
sensitivity and PPV (SAS/STAT V.12.1, SAS Institute,
Cary, North Carolina, USA).
Linked hospital data
We examined the effect of a look-back period to distin-
guish incident cases from prevalent cases ascertained
from the hospital data in the APEDDR by calculating
the number of people with a ‘first’ admission for pancre-
atic or periampullary cancer with look-back periods
increasing by increments of 6 months up to a period of
5 years using 2009 and 2013 as index years.
RESULTS
Accuracy of hospital diagnoses
Overall, the sensitivity of case ascertainment of registry
recorded cases of pancreatic and periampullary cancer
cases for the 2005–2009 period from the hospital data
was 87.5% (4322/4939) and was highest (97.9%, 715/
730) for people who underwent resection (table 1). The
lowest sensitivity (9.6%, 18/187) was for cases notified to
the registry by death certificate only. Most cases (71.1%,
133/187) with death certificate-only notifications were
among people 80 years or older, and this age group had
lower sensitivity (83.2%, 1271/1528) for hospital ascer-
tainment than younger age groups. Lower sensitivity was
observed for people residing outside of major cities,
with inner and outer regional areas having the lowest
sensitivity (83.3%). Further exploration of the geo-
graphic variation in case ascertainment found that sensi-
tivity ranged from 55.0% to 92.6% across regional and
remote administrative health districts (not shown).
Sensitivity was highest for localised (95.9%, 805/839)
cancers, followed by cancers with regional (93.3%, 846/
907) and distant (89.5%, 1863/2082) extent of disease
and was lowest for cases where the extent was recorded as
unknown on the registry (72.7%, 808/1111). Across
primary tumour sites, sensitivity was higher for pancreatic
(88.6%, 3733/4211) and duodenal cancers (87.1%, 162/
186) compared with extrahepatic bile duct and ampullary
cancers (78.8%, 427/542), particularly those of the cho-
langiocarcinoma histology type (67.9%, 131/193).
Of the cases on the registry without an admission with
pancreatic or periampullary cancer recorded (false
negatives, n=617), 42.9% (n=265) of people did not
have a hospital admission in the month prior to diagno-
sis or any time after in the 2005–2009 period (table 2).
The number of false negatives was affected by only
including admissions up to the end of 2009, with the
sensitivity of case ascertainment for cases diagnosed in
2009 lower (85.6%, 860/1005) than the preceding years.
People diagnosed in 2009 who had their first admission
for cancer in 2010 would be classified as false negatives.
Of false-negative cases with an admission (n=352), diag-
noses recorded in hospital admissions included cancer
of ill-defined or unspecified site (22.7%, 80/352), intra-
hepatic bile duct carcinoma (13.9%, 49/352) and non-
cancer diagnoses (table 2).
A total of 5272 people had an admission with pancre-
atic or periampullary cancer recorded in the linked hos-
pital to registry data in the 2005–2009 period, giving a
PPV of 82.0% (4322/5272; 95% CL 80.9% to 83.0%). Of
the false positives (n=950), 50.5% (n=480) had a pancre-
atic or periampullary cancer case recorded on the regis-
try diagnosed prior to 2005 (table 2). For these cases,
the pancreatic or periampullary cancer diagnoses
recorded on the hospital admission was correct;
however, the cases were prevalent cases rather than inci-
dent cases in the 2005–2009 period. Of the other false
positives, one-fifth (22.8%, 107/470) of people had an
intrahepatic bile duct carcinoma and another fifth
(21.1%, 99/470) had an ill-defined or unspecified
primary site cancer case recorded on the registry. Nine
false positives (1.9%, 9/470) had a pancreatectomy
recorded. These estimates of false positives in the hos-
pital data only include people with a linked invasive
cancer case in the registry data; therefore, the number
of false positives may be underestimated.
We compared the classification of the primary site allo-
cated from the hospital data with the site recorded on
the registry (table 3). One per cent (41/3945) of cases
allocated as a pancreatic cancer using hospital diagnoses
were true periampullary cancer cases, whereas 12.5%
(106/847) of cases allocated as periampullary using hos-
pital diagnoses were true pancreatic cancer cases. The
misclassification of periampullary cancers was greater
since any person with an admission with a periampullary
cancer diagnosis recorded was allocated as periampul-
lary regardless of if they also had a pancreatic cancer
diagnosis recorded in another admission.
Ascertaining incident cases from hospital data
Around one-quarter of cases ascertained from the linked
hospital data (APEDDR) were misclassified as an incident
case without any look-back period (figure 2). Two years
of look-back was sufficient to distinguish the majority
(98%) of incident cases from prevalent cases, which was
similar for pancreatic and periampullary cancers or pan-
creatic cancers only. For example, 1.8% (21/1193) of
people classified as having an ‘incident’ pancreatic or
periampullary cancer case in 2013, using a 2-year look-
back period, were identified as prevalent cases when a
5-year look-back period was used. The number of cases
ascertained from the APEDDR for the 2005–2009 period,
using all available data to July 2000 as a look-back period,
was 4970, which is within 1% of the number of cases
recorded on the registry for this period (n=4939).
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DISCUSSION
We found sensitivity for the ascertainment of pancreatic
and periampullary cancer cases from the hospital data
of 87.5% for the 2005–2009 period. The accuracy of hos-
pital coding varied by tumour primary site and histology,
with higher sensitivity of case ascertainment for pancre-
atic (88.6%) and duodenal cancers (87.1%) compared
with extrahepatic bile duct and ampullary cancers
(78.8%) and with lower sensitivity for extrahepatic cho-
langiocarcinomas (67.9%). Misclassification of pancre-
atic and periampullary cancers in the hospital data was
often to closely related sites, for example, intrahepatic
bile duct carcinoma, or to less specific sites such as
cancers of ill-defined or unspecified primary sites.
Whereas hospital coders might only have information
from a particular admission available, coders at a cancer




the hospital data* Sensitivity (%) 95% CL
Year of diagnosis
2005 973 850 87.4 (85.1 to 89.4)
2006 926 827 89.3 (87.1 to 91.2)
2007 1034 907 87.7 (85.6 to 89.7)
2008 1001 878 87.7 (85.5 to 89.7)
2009 1005 860 85.6 (83.2 to 87.7)
Age at diagnosis (years)
<50 246 221 89.8 (85.4 to 93.3)
50 to 59 591 519 87.8 (84.9 to 90.3)
60 to 69 1087 973 89.5 (87.5 to 91.3)
70 to 79 1487 1338 90.0 (88.3 to 91.5)
80+ 1528 1271 83.2 (81.2 to 85.0)
Remoteness of residence
Major city 3447 3078 89.3 (88.2 to 90.3)
Inner regional 1091 909 83.3 (81.0 to 85.5)
Outer regional 366 305 83.3 (79.1 to 87.0)
Remote and very remote 35 30 85.7 (69.7 to 95.2)
Primary site
Pancreas (C25) 4211 3733 88.6 (87.7 to 89.6)
Extrahepatic bile duct and ampulla (C24) 542 427 78.8 (75.1 to 82.2)
Duodenum (C17.0) 186 162 87.1 (81.4 to 91.6)
Histology type
Adenocarcinoma 2629 2388 90.8 (89.7 to 91.9)
Cholangiocarcinoma 193 131 67.9 (60.8 to 74.4)
Neuroendocrine 144 118 81.9 (74.7 to 87.9)
Other 45 40 88.9 (75.9 to 96.3)
Unspecified 1928 1645 85.3 (83.7 to 86.9)
Extent of disease
Localised 839 805 95.9 (94.4 to 97.2)
Regional 907 846 93.3 (91.4 to 94.8)
Distant 2082 1863 89.5 (88.1 to 90.8)
Unknown 1111 808 72.7 (70.0 to 75.3)
Best basis of diagnosis†
Histopathology 2761 2510 90.9 (89.8 to 92.0)
Cytology 481 407 84.6 (81.1 to 87.7)
Clinical 1507 1387 92.0 (90.6 to 93.4)
Death certificate only 187 18 9.6 (5.8 to 14.8)
Resection status
No resection 4209 3607 85.7 (84.6 to 86.7)
Resection 730 715 97.9 (96.6 to 98.8)
Overall 4939 4322 87.5 (86.6 to 88.4)
*Registry cases with a diagnosis of pancreatic or periampullary cancer recorded in an admission. We did not measure the concordance of
variables between the two data sources.
†Cases (n=3) notified by postmortem only are not shown. Cases notified to the New South Wales Central Cancer Registry (NSW CCR) by
death certificate only were unavailable for 2009.22 Death certificate-only notified cases were 4.8% (187/3934) of cases for the 2005–2008
period.
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registry often have multiple sources of information from
diagnostic procedures and treatment which can enable
more accurate coding of tumour characteristics.
Several aspects of the coverage of the hospital data
affected the ascertainment of cancer cases. In particular,
only admissions in NSW hospitals were available.
Variation in sensitivity across regional and remote admin-
istrative health areas most likely reflects patterns of inter-
state patient outflows since cases will not be ascertained
from NSW hospital data for people who have all of their
inpatient treatment outside of NSW. The population-level
coverage of the hospital data must be assessed with geo-
graphic areas with insufficient coverage unsuitable for
cancer case ascertainment from hospital data. Conversely,
the NSW cancer registry achieves complete population
coverage since NSW residents treated in other jurisdic-
tions are notified to the NSW cancer registry by the statu-
tory population-based cancer registry in that jurisdiction,
with Australia having full population coverage by statutory
cancer registries. Another factor affecting case
ascertainment is the inclusion in the registry of cases noti-
fied by death certificate only, where the sensitivity of
ascertainment from hospital data was low (9.6%). The
accuracy of diagnostic information may be lower for cases
when a death certificate is the only source of information,
but nevertheless they are recorded by population-based
cancer registries to capture comprehensive incidence
data for a population.26
Pancreatic and periampullary cancers are good candi-
dates for ascertainment from hospital admission data
since diagnosis, treatment or symptom management is
likely to require hospitalisation during the course of the
disease. Sensitivity was highest (97.9%) for the minority
of people (15%) who underwent curative resection.
Hospitalisation to relieve biliary or gastric obstruction by
stenting or bypass surgery or to manage pain and nutri-
tion is commonly required in the management of these
cancers.27 28 Chemotherapy, which is indicated for
people with unresectable disease,28 is mostly delivered in
an outpatient setting in NSW and therefore is largely not
Table 2 Diagnoses (International Statistical Classification of Diseases and Related Health Problems, 10th Revision,





Intrahepatic bile duct carcinoma (cholangiocarcinoma) (C22.1) 49 (7.9)
Gallbladder cancer (C23) 10 (1.6)
Cancer of ill-defined or unspecified site (C26, C76, C80) 80 (13.0)
Secondary cancer of the liver, other or unspecified digestive organ (C78.7, C78.8) 23 (3.7)
Neoplasms with in situ, benign, uncertain or unknown behaviour of the pancreas, small
intestine, biliary tract, ill-defined or unspecified digestive organs†
29 (4.7)
Calculus of the bile duct and other biliary tract diseases (K80.3-5, K83) 54 (8.8)
Acute pancreatitis and other diseases of the pancreas (K85, K86) 11 (1.8)
Other diagnosis 96 (15.6)




Pancreatic or periampullary cancer diagnosed prior to 2005 480 (50.5)
Intrahepatic bile duct carcinoma (cholangiocarcinoma) (C22.1) 107 (11.3)
Gallbladder cancer (C23) 47 (4.9)
Cancer of ill-defined or unspecified site (C26, C76, C80) 99 (10.4)
Other cancer 217 (22.8)
*People had more than one diagnosis category recorded in admissions. The category was assigned hierarchically to avoid double counting
people.
†D01.5, D01.7, D01.9, D13.2-9, D37.2, D37.6, D37.7, D37.9.
Table 3 Primary site (International Statistical Classification of Diseases and Related Health Problems, 10th Revision,
Australian Modification, ICD-10-AM) of registry and hospital cases, 2005–2009
Hospital primary site
False negatives* Periampullary cancer Pancreatic cancer Total
Registry primary site
False positives† 0 193 277 470
Periampullary cancer 112 548 41 701
Pancreatic cancer 240 106 3627 3973
Total 352 847 3945 5144
*People who did not link to a hospital admission are excluded from the false negatives (n=265).
†People who linked to a pancreatic or periampullary cancer diagnosed prior to 2005 are excluded from the false positives (n=480).
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captured in hospital admission data. This may lead to
underascertainment of cases from hospital admission
data when chemotherapy is the only therapy required
for management of the cancer. Multiple hospitalisations
for the management of these cancers mean that preva-
lent cases need to be distinguished from incident cases
in the hospital data. The PPV estimated in this study
(82.0%) was impacted by this pattern of multiple hospi-
talisations. On examination, half of the false positives in
the hospital data were true pancreatic or periampullary
cancer cases but were people with a prevalent rather
than an incident case for the 2005–2009 period. The
PPV could be improved by the use of a minimum 2-year
look-back period to identify a person’s first admission
for cancer, which we found was sufficient to distinguish
the majority of incident cases from prevalent cases.
We were able to calculate a PPV; however, it may be an
underestimate since we could only identify people with a
hospital admission for pancreatic or periampullary
cancer who had a cancer case recorded on the NSW
cancer registry between 1994 and 2009. Therefore, false
positives in the hospital data without any cancer
registry-recorded case were not ascertained, which is a
limitation of our study. We do not expect the underesti-
mation of false positives to be substantial, however, since
the number of incident cases ascertained from the
APEDDR was similar to the number of cases recorded
on the registry for the 2005–2009 period.
Few studies have examined the validity of ascertaining
pancreatic cancer cases from hospital data, with none
examining periampullary cancers. Our study compares
favourably to a study in the USA which reported sensitiv-
ity for pancreas cancer of up to 86% using inpatient
Medicare claims data.29 A NSW study reported sensitivity
for pancreas cancer of 94.7% and a PPV of 80.9% for
admission data from public hospitals in one administra-
tive health district.20 A strength of our study was that it
used population-based registry data as the ‘gold stand-
ard’ and included both public and private hospital data.
Without coverage of public and private hospitals, we
expect there would have been substantial underascer-
tainment of cases, as was found by another study.11 Our
study is relevant to jurisdictions with administrative hos-
pital data with population coverage and standardised
coding in place. Incident breast, colorectal and lung
cancer case data obtained from administrative hospital
records have been found to be of sufficient quality for
informing health services research in other
jurisdictions.8 9 12
Internationally, pancreatic cancer has been the subject
of health system performance improvement pro-
grammes16–19 since studies have identified underuse of
curative resection30 31 and variation across hospitals in
morbidity, mortality and survival outcomes following
surgery, particularly in relation to hospital volume.32
Programmes have generally established recommended
minimum hospital volumes with the aim of increasing
access to expert multidisciplinary care and improving
patient outcomes. Measuring if these minimum volumes
are met, changes to the per cent of people receiving cura-
tive surgery and changes in outcomes are key compo-
nents of monitoring the implementation of these
programmes.17–19 Our study demonstrates that NSW hos-
pital data are of sufficient quality to inform aspects of the
development and monitoring of a service improvement
programme for pancreatic surgery for cancer. For
example, the data are adequate for measurement of hos-
pital volume of pancreatic cancer surgery, overall postsur-
gical outcomes (when linked to death registry data) and
resection rates for population groups with good coverage
in the hospital data. Hospital admission data, however,
lack a date of cancer diagnosis and detailed clinical infor-
mation, such as tumour size and vascular involvement,
which are required to measure postdiagnosis survival and
perform risk adjustment of outcomes with minimum
residual confounding for case complexity.
CONCLUSION
Pancreatic and periampullary cancer cases can be ascer-
tained from hospital admission data where coding stan-
dards are applied and there is population coverage. The
pattern of hospitalisation for these cancers mean that
linked hospital data, in which multiple admissions for the
same person can be identified, and a sufficient look-back
period are required to distinguish incident cases from
prevalent cases. Our study indicates that hospital-derived
case and resection data have sufficient validity to inform
Figure 2 Effect of a look-back period on the estimates of
incident cases from hospital admission data, 2009 and 2013
index years.
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aspects of health system performance planning and mon-
itoring for pancreatic cancer. However, case ascertain-
ment differs across population subgroups and the clinical
variables are limited. Cancer registry data with
population-level coverage and clinical information are
required for some health system performance measures.
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